Shares of Denali Therapeutics (NASDAQ:DNLI) have earned a consensus recommendation of “Buy” from the six analysts that are currently covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $24.00.
DNLI has been the topic of several research reports. Zacks Investment Research raised Denali Therapeutics from a “hold” rating to a “buy” rating and set a $21.00 price objective on the stock in a research report on Tuesday, April 3rd. ValuEngine raised Denali Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd.
Shares of DNLI traded up $0.29 during trading hours on Wednesday, hitting $19.27. The stock had a trading volume of 82,461 shares, compared to its average volume of 265,348. Denali Therapeutics has a 12-month low of $14.72 and a 12-month high of $25.79.
Denali Therapeutics (NASDAQ:DNLI) last issued its earnings results on Monday, March 19th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.47). equities research analysts expect that Denali Therapeutics will post -0.56 EPS for the current year.
A number of large investors have recently added to or reduced their stakes in DNLI. Crestline Management LP purchased a new position in Denali Therapeutics in the fourth quarter valued at about $321,782,000. Flagship Pioneering Inc. purchased a new position in Denali Therapeutics in the fourth quarter valued at about $139,489,000. Artal Group S.A. acquired a new stake in shares of Denali Therapeutics during the fourth quarter valued at about $7,820,000. Bamco Inc. NY acquired a new stake in shares of Denali Therapeutics during the fourth quarter valued at about $7,664,000. Finally, Bridger Management LLC acquired a new stake in shares of Denali Therapeutics during the fourth quarter valued at about $4,888,000. 60.97% of the stock is currently owned by institutional investors.
About Denali Therapeutics
Denali Therapeutics Inc, a biopharmaceutical company, engages in discovering and developing therapeutics for neurodegenerative diseases in the United States. The company's lead LRRK2 product candidates includes the DNL201, a small molecule inhibitor that is in Phase I clinical trials, as well as DNL151, a small molecule inhibitor, which is in preclinical development stage for the treatment of Parkinson's disease.
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.